Porvenir · Product for Pharmaceutical & Biotech Companies
App Store Rating and Reviews Declining
for
Pharmaceutical & Biotech Companies.
Your app's rating has been slipping, and it's starting to hurt visibility.
Fixed for pharmaceutical & biotech companies. Pharmaceutical and biotech companies must build scientific credibility and investor confidence simultaneously.
Signs pharmaceutical & biotech companies recognise
Does this sound
familiar?
Why this hits pharmaceutical & biotech companies hardest
Sector-specific
pressure points.
Brand not communicating scientific rigour and clinical credibility to investors and KOLs
No digital strategy for building awareness with HCPs before a product launch
Website failing to explain complex mechanism-of-action in terms stakeholders understand
No content strategy building authority in a competitive therapeutic area
Our approach
How we fix it
for pharmaceutical & biotech companies.
Review & Feedback Audit
We analyse recent reviews and support tickets to find the specific, recurring issues driving the decline.
Fix the Root Issues
We prioritise and fix the underlying bugs or experience issues actually driving negative reviews.
Review Generation Strategy
We put a compliant, well-timed prompt strategy in place to encourage satisfied users to leave reviews.
Monitor & Respond
We help set up a process for monitoring and responding to reviews going forward, catching issues early.
What pharmaceutical & biotech companies gain
Real outcomes.
A measurable recovery in average app rating over time
Root-cause issues fixed rather than just review-count damage control
An ongoing process for review monitoring and generation
FAQ
Common questions.
Do you specifically fix app store rating and reviews declining for pharmaceutical & biotech companies?
Yes. We understand the specific commercial context pharmaceutical & biotech companies operate in, and we apply that context directly to how we fix app store rating and reviews declining.
What causes app store rating and reviews declining for a pharmaceutical & biotech?
A buggy or poorly tested update that shipped with unresolved issues These issues tend to compound for pharmaceutical & biotech companies because of brand not communicating scientific rigour and clinical credibility to investors and kols.
How quickly can you fix app store rating and reviews declining for our pharmaceutical & biotech?
Most engagements addressing app store rating and reviews declining for pharmaceutical & biotech companies show measurable movement within 30–60 days, with the full fix delivered over 4–10 weeks depending on scope.
What results should a pharmaceutical & biotech expect?
A measurable recovery in average app rating over time Root-cause issues fixed rather than just review-count damage control
Do you work with pharmaceutical & biotech companies outside our home market?
Yes - we work with pharmaceutical & biotech companies across North America, the UK, UAE, Europe, and Asia Pacific, delivered fully remotely.
Explore more
Related pages.
Other Problems We Solve for Pharmaceutical & Biotech Companies
- MVP Development for Pharmaceutical & Biotech Companies
- Mobile App Not Getting Downloads for Pharmaceutical & Biotech Companies
- Product Launch Underperformed for Pharmaceutical & Biotech Companies
- AI Features Not Adding Real Value for Pharmaceutical & Biotech Companies
- No Clear AI Strategy for Pharmaceutical & Biotech Companies
- High User Onboarding Drop-Off for Pharmaceutical & Biotech Companies
App Store Rating and Reviews Declining for Pharmaceutical & Biotech Companies
Ready to fix
this for your pharmaceutical & biotech?
Book a discovery call. No pitch, no pressure - just a focused conversation about where you are and where you want to be.